---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-003929"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:22:19.652478+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Crinetics outlines 2024 milestones: paltusotine Phase 3 data Q1, CRN04894 data Q2

## Summary
- Phase 3 PATHFNDR-2 trial of paltusotine in acromegaly on track for topline data in Q1 2024.
- Phase 2 trial of paltusotine in carcinoid syndrome topline data expected H1 2024; Phase 3 start H2 2024.
- Phase 2 trials of CRN04894 (ACTH antagonist) in CAH and Cushing's disease initial data expected Q2 2024.
- Preclinical evaluation ongoing for oral small molecules in hyperparathyroidism, PKD, Graves', TED, diabetes, and obesity.
- CEO to present at J.P. Morgan Healthcare Conference on Jan 9, 2024.

## SEC filing metadata
- accession: 0001193125-24-003929
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000119312524003929/0001193125-24-003929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000119312524003929/d706423d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-003929
- JSON: https://secwatch.observer/filing/0001193125-24-003929.json
- Plain text: https://secwatch.observer/filing/0001193125-24-003929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.